EXPERIMENTAL THERAPY OF HOMOZYGOUS PROTEIN C DEFICIENCY

纯合蛋白 C 缺乏症的实验治疗

• 批准号: 3884271
• 负责人: WILLIAM E HATHAWAY
• 金额: --
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3884271
• 关键词: anticoagulants; blood coagulation disorders; blood disorder chemotherapy; child (0-11); clinical trials; congenital blood disorder; congenital blood protein disorder; homozygote; human subject; human therapy evaluation; protein C; venous thrombosis

Homozygous c deficiency is currently a fatal disorder with death from recurrent purpura fulmains and massive venous thrombosis occurring in the first few years of life. This protocol will employ aggressive oral anticoagulation in an attempt to control progressive thrombosis.

纯合子c缺乏症目前是一种致命的疾病，死亡原因是 复发性紫癜性黄斑和大范围静脉血栓形成 生命的最初几年。这项协议将使用攻击性口头 抗凝，试图控制进行性血栓形成。